
Fmoc-Val-Cit-PAB-MMAE
CAS No. 1350456-56-2
Fmoc-Val-Cit-PAB-MMAE( —— )
Catalog No. M23511 CAS No. 1350456-56-2
Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 138 | In Stock |
![]() ![]() |
10MG | 222 | In Stock |
![]() ![]() |
25MG | 401 | In Stock |
![]() ![]() |
50MG | 593 | In Stock |
![]() ![]() |
100MG | 844 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameFmoc-Val-Cit-PAB-MMAE
-
NoteResearch use only, not for human use.
-
Brief DescriptionFmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
-
DescriptionFmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorAuristatin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1350456-56-2
-
Formula Weight1345.67
-
Molecular FormulaC73H104N10O14
-
Purity>98% (HPLC)
-
SolubilityDMSO:30 mg/mL (22.29 mM)
-
SMILESCC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)OCC4C5=CC=CC=C5C6=CC=CC=C46
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog



related products
-
Fmoc-NH-PEG8-NHS est...
Fmoc-NH-PEG8-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Amino-PEG11-amine
Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.
-
Amino-PEG4-Boc
Amino-PEG4-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.